JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hardin, J. S.
Right arrow Articles by Owens, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hardin, J. S.
Right arrow Articles by Owens, S. M.

Vol. 302, Issue 1, 119-126, July 2002

A Single Dose of Monoclonal Anti-Phencyclidine IgG Offers Long-Term Reductions in Phencyclidine Behavioral Effects in Rats

J. Shane Hardin1, William D. Wessinger, Galen R. Wenger, Joel W. Proksch2, Elizabeth M. Laurenzana and S. Michael Owens

Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas

These studies tested the hypothesis that a single dose of high-affinity anti-phencyclidine monoclonal antibody (anti-PCP mAb) provides long-term protection against behavioral effects of repeated PCP administration in rats. Rats were treated with saline, nonspecific bovine IgG (NS-IgG), or anti-PCP mAb (1.0 g/kg). The next morning, the rats were challenged with escalating i.v. doses of PCP (0.32, 0.56, and 1.0 mg/kg) at 90-min intervals. This regimen was repeated every 3 days for 2 weeks. In the saline and NS-IgG control groups, PCP yielded reproducible and linear dose-dependent effects that remained constant during the experiment. In contrast, the anti-PCP mAb treatment blocked PCP effects on day 1, and sustained significant (P < 0.05) reductions in drug effects for the entire 2-week experiment. Brain PCP concentrations (determined at study termination) were reduced by ~55%, whereas serum concentrations were increased over 4000% compared with controls. Thus, a single dose of antibody medication provided long-term reductions in drug effects and brain concentrations, beyond the expected capacity of the drug-antibody interaction. These data challenge current concepts about in vivo dose dependence and unimolecular interaction between antibody binding sites and small molecules and establish that neuroprotection by mAbs may have an unique mechanism of action.

1  Current address: Department of Emergency Medicine, Pitt County Memorial Hospital, Greenville, NC 27835.

2  Current address: Molecumetics, 2023 120th Avenue NE, Bellevue, WA 98005.

0022-3565/02/3021-0119$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
S. A. Roiko, A. C. Harris, D. E. Keyler, M. G. LeSage, Y. Zhang, and P. R. Pentel
Combined Active and Passive Immunization Enhances the Efficacy of Immunotherapy against Nicotine in Rats
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 985 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
G. Pitas, E. M. Laurenzana, D. K. Williams, S. M. Owens, and W. B. Gentry
ANTI-PHENCYCLIDINE MONOCLONAL ANTIBODY BINDING CAPACITY IS NOT THE ONLY DETERMINANT OF EFFECTIVENESS, DISPROVING THE CONCEPT THAT ANTIBODY CAPACITY IS EASILY SURMOUNTED
Drug Metab. Dispos., June 1, 2006; 34(6): 906 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. E. Keyler, S. A. Roiko, E. Benlhabib, M. G. LeSage, J. V. St. Peter, S. Stewart, S. Fuller, C. T. Le, and P. R. Pentel
MONOCLONAL NICOTINE-SPECIFIC ANTIBODIES REDUCE NICOTINE DISTRIBUTION TO BRAIN IN RATS: DOSE- AND AFFINITY-RESPONSE RELATIONSHIPS
Drug Metab. Dispos., July 1, 2005; 33(7): 1056 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. E. McMillan, W. C. Hardwick, M. Li, M. G. Gunnell, F. I. Carroll, P. Abraham, and S. M. Owens
Effects of Murine-Derived Anti-Methamphetamine Monoclonal Antibodies on (+)-Methamphetamine Self-Administration in the Rat
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1248 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. M. Laurenzana, K. A. Byrnes-Blake, A. Milesi-Halle, W. B. Gentry, D. K. Williams, and S. M. Owens
USE OF ANTI-(+)-METHAMPHETAMINE MONOCLONAL ANTIBODY TO SIGNIFICANTLY ALTER (+)-METHAMPHETAMINE AND (+)-AMPHETAMINE DISPOSITION IN RATS
Drug Metab. Dispos., November 1, 2003; 31(11): 1320 - 1326.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. M. Laurenzana, M. G. Gunnell, W. B. Gentry, and S. M. Owens
Treatment of Adverse Effects of Excessive Phencyclidine Exposure in Rats with a Minimal Dose of Monoclonal Antibody
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1092 - 1098.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.